Neurocrine Biosciences generated $3.1B in trailing twelve-month revenue, up 0.3% year-over-year. Net income was $668.6M with a 21.55% net margin. Gross margin stands at 98.17% and operating margin at 25.43%. Diluted EPS is $6.49, which grew 1.2% year-over-year. Based on the Q1 2026 filing.